Pharmafile Logo
Pharmafocus logo
Advanced Search

Pfizer and Spark Therapeutics present early data on bio-engineered haemophilia drug

May 23, 2016
Research and Development, Sales and Marketing Pfizer, Spark Therapeutics, gene therapy, haemophilia B

Pfizer (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) have announced that they will present data showing encouraging signs in their …

News
pfizer_finland_hq

EMA to review Pfizer’s meningococcal vaccine

May 20, 2016
Research and Development, Sales and Marketing EMA, Pfizer, meningitis, meningococcal vaccine, trumenba

Pfizer (NYSE: PFE) has announced that the European Medicines Agency has accepting the marketing authorisation application for its meningococcal group …

News
msf

MSF says staff member shot dead in Central African Republic; suspends activity in the area

May 20, 2016
Medical Communications Central African republic, MSF

The medical aid charity Doctors without Borders (MSF) said it is suspending activities in the Central African Republic (CAR) following an …

News
novartis_side_building

Nice backs Novartis’ lung cancer drug

May 20, 2016
NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation

The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for …

News
money_pills_2

Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug

May 20, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights

Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …

News
roche_glass_building

UK regulators do not back Roche’s breast cancer drug

May 20, 2016
Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer, recommendation

The National Institute for Health and Care Excellence (Nice) has provisionally turned down Swiss drugmaker Roche’s (VTX: ROG) breast cancer …

News
chugai_pharmaceutical

Chugai partners with Osaka University in £62 million immunology collaboration

May 20, 2016
Medical Communications, Research and Development Chugai, collaboration, immunology, osaka university

Chugai Pharmaceuticals (TOKYO: 4519) has announced a collaboration agreement with Osaka University in advanced immunology research worth up to £62 …

News
clinical_trial_3

Celator receives FDA breakthrough therapy designation for leukaemia drug

May 20, 2016
Medical Communications, Research and Development FDA, Vyxeos, acute myeloid leukaemia, breakthrough therapy, celator

A new treatment for acute myeloid leukaemia and other blood cancers from Celator Pharmaceuticals (NASDAQ: CPXX) has been granted breakthrough …

News

Urgent action needed on antimicrobial resistance, says government report

May 19, 2016
Manufacturing and Production, Medical Communications, Research and Development ABPI, Lord Jim O'Neill, NICE, antimicrobial resistance

A new UK governmental report has warned that the global rise of antimicrobial resistance is set to worsen, with the …

News

Germany’s Merck Q1 profits double boosted by Sigma-Aldrich deal

May 19, 2016
Business Services, Sales and Marketing Financial, Merck, Q1, Sigma-Aldrich, deal, earnings, results

Germany’s Merck on Thursday said first-quarter net profit more than doubled helped by the integration of US laboratory equipment maker …

News
clinical_trial_3

Darzalex meets endpoint in late-stage multiple myeloma trial

May 19, 2016
Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial

Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …

News
bmslogo

BMS says Phase III trials for Opdivo show improved overall survival in lung cancer

May 19, 2016
Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo

Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …

News

Bayer makes bid for Monsanto

May 19, 2016
Manufacturing and Production, Sales and Marketing Bayer, agrochemical, bid, monsanto, takeover

Bayer (ETR: BAYN) has made a move to consolidate its position in the agrochemical sector with an unsolicited takeover bid …

News
rocheshanghai

FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq

May 19, 2016
Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq

Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …

News
roche__tree

Roche confirms over 200 job cuts at Irish facility

May 18, 2016
Manufacturing and Production Roche, clare, clarecastle, closure, irish site, job cuts, job losses

Swiss pharmaceutical company Roche (VTX: ROG) has confirmed that 240 jobs are to go at their Irish site in Clare, …

News

AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials

May 18, 2016
Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III

AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …

News
sample

Breast cancer trial stopped after meeting primary endpoint early

May 18, 2016
Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib

A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …

News
bi_german_building_at_night

Boehringer Ingelheim says new studies underline efficacy of lung disease drug

May 18, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease

Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …

News

Novartis splits pharmaceuticals division into two business units

May 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Novartis, epstein, new division

Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis …

News
opdivo_1

Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma

May 18, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo

Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …

News
The Gateway to Local Adoption Series

Latest content

Sandoz launches allergy relief nasal spray in Germany and Switzerland

April 9, 2026

Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer

April 9, 2026

Trelleborg to take part in Medtec Japan 2026

April 8, 2026

Kainova Therapeutics expands phase I/II trial of antibody drug

April 7, 2026

Eisai starts enrolment for phase 2 narcolepsy study evaluating E2086

April 7, 2026